-
Merimepodib (VX-497): IMPDH Workflow Guide
2026-09-16
Merimepodib (VX-497) is a versatile IMPDH probe for connecting guanine-nucleotide depletion with lymphocyte proliferation, tumor-cell growth, and virus replication. This practical guide combines assay setup, guanosine-rescue logic, PEDV-focused antiviral workflows, and troubleshooting for more interpretable results.
-
Budesonide: Choosing Better Pulmonary Membrane Models
2026-09-16
Budesonide is an anti-inflammatory corticosteroid widely used to interrogate airway inflammation and glucocorticoid responses. This guide translates comparative IAM LC and LEKC evidence into a practical framework for selecting permeability assays without confusing membrane transport with anti-inflammatory efficacy.
-
Carvedilol Phosphate in Hepatic IRI Models
2026-09-15
Build reproducible ischemia–reperfusion assays with Carvedilol Phosphate as a controlled adrenergic signaling perturbation rather than an assumed therapeutic mimic. This workflow connects compound preparation, hypoxia–reoxygenation experiments, hepatocyte–macrophage communication, and 6-ketoLCA analysis while clearly separating established findings from practical starting conditions.
-
Hydrocortisone Butyrate: From GR to Delivery
2026-09-15
Hydrocortisone butyrate is more than a glucocorticoid receptor agonist for inflammation assays. This thought-leadership guide connects receptor biology, dermatitis and epidermal models, and PLGA-based controlled delivery while showing how ester stability and exposure design shape translational interpretation.
-
CX-4945: CK2 Inhibition Beyond Tumor Cells
2026-09-14
CX-4945 (Silmitasertib) is a selective CK2 inhibitor that connects cancer-signaling research with emerging studies of neuroinflammation. This guide translates recent CSNK2A1 pathway findings into practical assay and interpretation strategies.
-
GRK Control of M1 Receptor Signaling Bias
2026-09-14
A 2025 study used dynamic BRET measurements to determine how GRK subtypes regulate M1 muscarinic receptor coupling to G proteins and β-arrestin 2. Its results show that the balance between GRK2/3 and GRK5/6 contributes to signaling bias and that BQCA changes acetylcholine responses primarily by shifting concentration–effect relationships.
-
Metoprolol: From Beta1 Blockade to Translation
2026-09-13
Metoprolol is more than a conventional cardiovascular tool: its selective beta1-adrenoceptor mechanism offers a disciplined framework for studying stress signaling, inflammation, tumor biology, and disease-state pharmacokinetics. This thought-leadership guide connects receptor pharmacology with translational study design while defining the evidentiary limits of cross-domain applications.
-
Phenacetin for Organoid Pharmacokinetic Studies
2026-09-12
Phenacetin provides a practical, chemically defined challenge for evaluating intestinal exposure, recovery, and solvent effects in organoid-based pharmacokinetic studies. Its limited water solubility makes formulation controls essential, while the PDK4 inhibitor literature offers a useful framework for separating target activity, metabolism, and translational assay readouts.
-
Budesonide: From Membrane Partition to Airway Models
2026-09-11
Budesonide is an anti-inflammatory corticosteroid widely used to interrogate airway inflammation and asthma biology. This article connects its pharmacology and handling requirements with biomimetic membrane assays, showing how assay choice can improve respiratory disease research.
-
Abiraterone Acetate in Patient-Derived Spheroids
2026-09-11
Explore how Abiraterone acetate can be evaluated as a CYP17 inhibitor in patient-derived prostate cancer spheroids. This evidence-focused guide explains why model qualification, compound identity, and orthogonal readouts are essential when translating androgen biosynthesis research into meaningful drug-response data.
-
Bismuth Subsalicylate in Cell Assay Workflows
2026-09-10
This scenario-driven guide explains how Bismuth Subsalicylate, SKU A8382, can be incorporated into cell viability, proliferation, and apoptosis workflows without confusing formulation artifacts with biological effects. It covers compound compatibility, controls, storage, orthogonal readouts, and practical vendor-selection criteria.
-
Merbromin as a Dual-Use Fluorescent Probe
2026-09-10
Merbromin is more than a fluorescent dye: it is a protein–ligand interaction probe, enzyme inhibition assay reagent, and environmentally relevant mercury-containing compound. This guide connects spectroscopic assay design with protease screening, antimicrobial research, and evidence from MOF-based pollutant removal.
-
Caffeic Acid Phenethyl Ester: NF-κB Assay Logic
2026-09-09
Caffeic Acid Phenethyl Ester (CAPE) is more than an NF-κB inhibitor: it is a strategic perturbation tool for separating inflammatory pathway contributions from Fyn–Stat3 neurodegeneration phenotypes. This guide connects assay design, chemical handling, and cross-domain validation in angiogenesis and tumor-invasion models.
-
Primidone: TRPM3 and RIPK1 Research Workflows
2026-09-09
Primidone, also known as Mysoline, supports complementary TRPM3 channel and RIPK1 workflows spanning neurodevelopmental, neurodegenerative, and inflammatory disease research. This guide translates its concentration-dependent activity into practical assay setup, animal-model dosing, biomarker selection, and troubleshooting strategies.
-
Phebestin Reveals a Dual Aminopeptidase Targeting Strategy
2026-09-08
The reference study identifies phebestin, a bestatin-related aminopeptidase inhibitor, as a nanomolar antiplasmodial candidate active against both chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum. By combining stage-specific culture assays, washout experiments, molecular docking, and two mouse infection models, the authors connect broad parasite inhibition with putative PfM1AAP and PfM17LAP engagement while also defining important gaps for future validation.